bl-b16d1
mAbexperimentalADCBi-specific
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 27, 2024 (NCT06469008)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
ERBB3 inhibitor
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06493864 | Phase 1 | Aug 26, 2024 | Baili Pharmaceutical Group, Fudan University |
| NCT06475131 | Phase 1 | Jul 18, 2024 | Baili Pharmaceutical Group, Sun Yat-Sen University |
| NCT06469008 | Phase 1 | Jun 27, 2024 | Baili Pharmaceutical Group, Huazhong University of Science and Technology |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 3 | 3 | 1 | 2024 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1